(See also the American Academy of Pediatrics' updated 2014 updated guidance for palivizumab prophylaxis for infants and young children who are at increased risk of hospitalization for RSV and 2022 updated guidance on the use of palivizumab prophylaxis to prevent hospitalization from severe RSV infection during the 2022 - 2023 RSV season.)